Key Performance
More- Earnings Score: N/A
- Momentum Score: 7
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
The global Peptide Drug Conjugate (PDC) market is projected to reach $1.5 billion by 2031, growing at over 14% CAGR from 2021-2025. PDCs offer targeted drug delivery solutions for oncology and other diseases with reduced systemic toxicity. The market features over 50 clinical candidates and 18 proprietary technologies, with major players including Novartis, Oncopeptides, Bicycle Therapeutics, Cybrexa Therapeutics, and PepGen driving innovation through strategic partnerships and technological advancements in peptide design and linker technologies.
04/21/2026, 4:31 AM • GlobeNewswire
S&P 500 Falls 1%; Accenture Posts Upbeat Earnings
U.S. stocks traded lower midday, with the S&P 500 dropping 1%. Accenture reported strong Q4 earnings, beating analyst estimates, while several other companies experienced significant stock price movements.
09/25/2025, 2:06 PM • Benzinga
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket
PepGen Inc. experienced a significant 112.4% pre-market stock surge after announcing an underwritten public offering of common stock and pre-funded warrants. Several other stocks showed notable pre-market movements, with some gaining and others declining.
09/25/2025, 6:11 AM • Benzinga
A class action lawsuit has been filed against PepGen alleging false and misleading statements about the company's drug PGN-EDO51, its CONNECT2 study effectiveness, and clinical prospects during the period of March 7, 2024 to March 3, 2025.
08/07/2025, 6:43 PM • GlobeNewswire
Law firm announces class action lawsuit against PepGen Inc. for allegedly making false and misleading statements about its drug PGN-EDO51 and clinical study CONNECT2 between March 2024 and March 2025.
08/07/2025, 4:00 PM • GlobeNewswire
PepGen (PEPG) Q2 Loss Narrows 19.5%
Biotechnology company PepGen reported Q2 2025 earnings with a narrower net loss of $(0.70) per share, better than analyst expectations. The company continues developing oligonucleotide therapies for neuromuscular diseases and expects to share clinical trial data in Q4 2025 and Q1 2026.
08/07/2025, 11:50 AM • The Motley Fool
A class action lawsuit has been filed against PepGen alleging false and misleading statements about their drug PGN-EDO51's effectiveness and safety during the period of March 7, 2024 to March 3, 2025.
08/05/2025, 6:58 PM • GlobeNewswire
Pomerantz LLP filed a class action lawsuit against PepGen Inc. for allegedly making false and misleading statements about its Duchenne muscular dystrophy drug PGN-EDO51, which failed to meet clinical trial expectations and was ultimately discontinued.
08/05/2025, 10:00 AM • GlobeNewswire
Rosen Law Firm reminds PepGen Inc. investors of an August 8, 2025 deadline to join a securities class action lawsuit, alleging the company made false statements about its drug PGN-EDO51's clinical research and effectiveness.
08/03/2025, 8:14 AM • GlobeNewswire
Rosen Law Firm is alerting PepGen Inc. investors about an August 8, 2025 deadline for a securities class action lawsuit, alleging the company made false and misleading statements about its drug PGN-EDO51 and clinical study effectiveness.
08/03/2025, 8:14 AM • GlobeNewswire
A class action lawsuit has been filed against PepGen regarding allegedly false statements about its drug PGN-EDO51's effectiveness and safety during the period of March 7, 2024 to March 3, 2025.
08/02/2025, 10:38 AM • GlobeNewswire
PepGen, a clinical-stage biotechnology company, faces a class action lawsuit alleging misleading statements about its DMD treatment PGN-EDO51, with stock price declines following disappointing clinical trial results and regulatory challenges.
08/01/2025, 3:36 PM • GlobeNewswire
A class action lawsuit has been filed against PepGen Inc. alleging false and misleading statements about its drug PGN-EDO51 for Duchenne muscular dystrophy, with the company facing significant stock price declines after revealing safety concerns and discontinuing its drug development program.
08/01/2025, 10:00 AM • GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen
Faruqi & Faruqi, LLP is investigating potential securities claims against PepGen Inc. regarding alleged false statements about its drug PGN-EDO51's clinical trial results and FDA approval prospects, which led to significant stock price declines.
07/30/2025, 5:41 PM • GlobeNewswire
A class action lawsuit has been filed against PepGen Inc. alleging false and misleading statements about the effectiveness and safety of their drug PGN-EDO51 and the CONNECT2 study during the period of March 7, 2024 to March 3, 2025.
07/29/2025, 4:00 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/03/2026
Company Profile
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.